A number of projects have accelerated the implementation of the national water network construction, and the South-to-North Water Transfer Project is a major strategic infrastructure to alleviate the serious shortage of water resources in northern China, and it is the main skeleton and artery of the national water network. On December 12th, the first phase of the East Middle Route of South-to-North Water Transfer Project ushered in the 10th anniversary of full water supply. The project has transferred more than 76.7 billion cubic meters of water, providing stable and high-quality water sources for 45 large and medium-sized cities and 185 million people in 7 provinces and cities along the route, and supporting the GDP growth of more than 16 trillion yuan in the northern region. The reporter was informed that in the next step, China will continue to promote the construction of major national water network projects, and a number of large reservoirs, large irrigation areas and other projects are being accelerated. (Economic Information Daily)A number of projects have accelerated the implementation of the national water network construction, and the South-to-North Water Transfer Project is a major strategic infrastructure to alleviate the serious shortage of water resources in northern China, and it is the main skeleton and artery of the national water network. On December 12th, the first phase of the East Middle Route of South-to-North Water Transfer Project ushered in the 10th anniversary of full water supply. The project has transferred more than 76.7 billion cubic meters of water, providing stable and high-quality water sources for 45 large and medium-sized cities and 185 million people in 7 provinces and cities along the route, and supporting the GDP growth of more than 16 trillion yuan in the northern region. The reporter was informed that in the next step, China will continue to promote the construction of major national water network projects, and a number of large reservoirs, large irrigation areas and other projects are being accelerated. (Economic Information Daily)Thirteen companies disclosed the progress of repurchase, among which Green Energy Huichong and Ruike had the highest amount of laser repurchase plans. On December 13th, a total of 13 companies issued announcements on stock repurchase. Among them, two companies disclosed the stock repurchase plan for the first time, four companies disclosed the progress of the implementation of stock repurchase, and seven companies have completed the implementation of the repurchase plan. Judging from the initial disclosure of the repurchase plan, Green Energy Huichong and Ruike Laser have the highest amount of repurchase plans, with the planned repurchase not exceeding 1.115 million yuan and 487,900 yuan respectively. Judging from the implementation progress of repurchase, Yuanli Technology, Jiuli Special Materials and Jack have the highest share repurchase amounts, with 33.1077 million yuan, 30.9807 million yuan and 3.2323 million yuan respectively. Judging from the completed repurchase, a total of one company repurchased more than 10 million on that day. Aerospace Rainbow, Aerospace Rainbow and Guanshi Technology have completed the highest repurchase amount, with 33.2989 million yuan, 2.479 million yuan and 2.1642 million yuan respectively.
Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.Onlikon: The cooperative product Aidit calcitonin soft capsules is planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13th, and on December 12th, the company received a notice from its partner Beijing Meifurun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Meifurun") that the Aidit calcitonin soft capsules jointly developed by the company and its wholly-owned subsidiary Wenzhou Haihe Pharmaceutical Co., Ltd. are planned to be selected for the tenth batch of national centralized drug procurement. According to the Pharmaceutical Cooperation Agreement signed by the company and its partner Mei Furun, the company owns 50% of the cooperative products.Apple is reported to cooperate with Broadcom to develop AI chips, and TSMC's advanced process will welcome big orders again. On December 13, it was reported that Apple intends to invest in self-developed AI chips, jointly develop them with Broadcom, and produce them in TSMC's 3 nm process, and mass-produce them in 2026. The legal person is optimistic that after the development of Apple's self-developed AI chip is completed, the investment is expected, and TSMC's advanced process will usher in another big order. It is understood that Apple's current A-series processors for iPhone and M-series processors for Mac all adopt self-developed strategies, and are exclusively manufactured by TSMC. The legal person believes that once Apple's self-developed chips are extended to AI chips, the cooperation with TSMC will be closer. (Taiwan Province Economic Daily)
Full-page observation of People's Daily: Accelerate the construction of world-class universities and advantageous disciplines with China characteristics.CITIC Securities: Relevant central state-owned enterprises engaged in business and equity cooperation with Huawei are expected to enjoy Huawei's empowerment. CITIC Securities pointed out that at the moment when the four sectors of intelligent selection are gathering together and the HI model is fully expanded, we believe that the investment core of Huawei's OEM is "change and invariance", that is, business model and partner iteration, but the top-level design of "not building cars, helping car companies build good cars" and the commercial appeal of maximizing sales and profits are not avoided. In addition, in the stage of deep cooperation with Huawei, the organizational structure and corporate governance of partners have been greatly improved. Similarly, we believe that relevant central state-owned enterprises engaged in business and equity cooperation with Huawei are expected to enjoy Huawei's empowerment, and Huawei will help the reform of state-owned enterprises.Haitong Securities: The moderate price reduction of traditional Chinese medicine varieties continues. The domestic pharmaceutical industry is expected to set off a wave of mergers and acquisitions. Haitong Securities released a research report saying that the moderate price reduction of traditional Chinese medicine varieties continues. In 2024, the traditional Chinese medicine industry was under pressure due to the pressure of pharmacy terminal sales and inventory pressure, and it is expected to return to a good situation in the next 25 years. In addition, the continuous technological changes in the pharmaceutical industry, the development of IPO to mergers and acquisitions and the promotion of corporate governance optimization at the shareholder level are the main reasons for promoting mergers and acquisitions in the industry. In terms of fields, mergers and acquisitions are expected to occur intensively in sub-sectors such as medical devices, Chinese medicine, medical services, blood products and scientific research services.
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14